EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

One Suppository, Fewer Admissions: Rectal Indomethacin and Post-ERCP Pancreatitis in 602 High-Risk Patients — A Nursing-Focused Secondary Analysis of a Randomised Trial

Abdulqadr Abdulrahman Rasool, Hardi Abdulqadir Hasan

Health Innovation Reports · 15.10.2026 · 2 (4) · 14-24

DOI: 10.64048/hir.v2n4.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Health Innovation Reports, online erschienen am 15.10.2026. Verfasst von Abdulqadr Abdulrahman Rasool und 1 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim: Pancreatitis is the most frequent serious complication of endoscopic retrograde cholangiopancreatography (ERCP), and nurses administer prophylaxis and monitor recovery. This study aimed to re-estimate the effect of rectal indomethacin on post-ERCP pancreatitis (PEP), to identify patient and procedural characteristics that independently predict PEP and to examine whether the benefit differed across clinically relevant subgroups.

Methods

This secondary analysis used an openly available, anonymised dataset from a multicentre, double-blind trial of 602 high-risk patients who received a single 100 mg dose of rectal indomethacin or placebo immediately after ERCP. Analyses were performed using Python, with chi-square and Mann–Whitney tests, risk ratios, hierarchical logistic regression and subgroup interaction tests.

Results

A total of 602 patients were analysed (295 indomethacin, 307 placebo; mean age 45.27 ± 13.30 years; 79.1% women). PEP occurred in 9.2% of patients who received indomethacin and 16.9% of those who received placebo (risk ratio 0.54, 95% CI 0.35 to 0.84; absolute risk reduction 7.7 percentage points; number needed to treat 13). Previous PEP (adjusted OR 2.71, 95% CI 1.49 to 4.91) and trainee involvement (adjusted OR 1.94, 95% CI 1.16 to 3.26) independently predicted PEP, while indomethacin halved the adjusted odds (adjusted OR 0.46, 95% CI 0.28 to 0.77). The benefit was consistent across all subgroups (all interaction p ≥ .196), and PEP rose from 7.7% to 22.3% across risk-score categories.

Conclusions

A single rectal dose of indomethacin nearly halved PEP in high-risk patients without increasing bleeding. Nursing protocols that verify prophylaxis for every eligible patient, flag those with previous PEP or trainee-performed procedures and extend observation for patients with multiple risk factors may provide a practical, evidence-based basis for safer peri-ERCP care.

Zitieren

APA

Rasool, A. A., & Hasan, H. A. (2026). One Suppository, Fewer Admissions: Rectal Indomethacin and Post-ERCP Pancreatitis in 602 High-Risk Patients — A Nursing-Focused Secondary Analysis of a Randomised Trial. Health Innovation Reports, 2(4), 14-24. https://doi.org/10.64048/hir.v2n4.003

Vancouver

Rasool AA, Hasan HA. One Suppository, Fewer Admissions: Rectal Indomethacin and Post-ERCP Pancreatitis in 602 High-Risk Patients — A Nursing-Focused Secondary Analysis of a Randomised Trial. Health Innovation Reports. 2026;2(4):14-24. doi:10.64048/hir.v2n4.003

BibTeX
@article{Rasool2026,
  author = {Rasool, Abdulqadr Abdulrahman and Hasan, Hardi Abdulqadir},
  title = {One Suppository, Fewer Admissions: Rectal Indomethacin and Post-ERCP Pancreatitis in 602 High-Risk Patients — A Nursing-Focused Secondary Analysis of a Randomised Trial},
  journal = {Health Innovation Reports},
  year = {2026},
  volume = {2},
  number = {4},
  pages = {14--24},
  doi = {10.64048/hir.v2n4.003}
}
Kostenlos starten →